Entries |
Document | Title | Date |
20080199448 | ENZYME COMPOSITION FOR IMPROVING FOOD DIGESTION - An orally administered composition for improving food absorption and digestion contains therapeutically effective dosages of digestive enzymes and L-glutamine as active ingredients. The digestive enzymes include at least one each of a lipase, a protease, and an amylase, and at least a portion of each of these enzymes is enteric coated. | 08-21-2008 |
20080219964 | Methods and products for enhancing energy and nutrition in human beings - Methods for increasing energy in men and women include ingesting internally, twice a day, products that include, for women, multivitamins, multiminerals, high-calcium bone support products, high-ORAC super food products, and enzymes, and, for men, multivitamins, multiminerals, prostate support products, high-ORAC super food products, and enzymes. | 09-11-2008 |
20080279839 | Composition With a Fungal (Yeast) Lipase and Method For Treating Lipid Malabsorption in Cystic Fibrous as Well as People Suffering From Pancreatic Lipase Insufficiency - The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from | 11-13-2008 |
20080299102 | Novel BACE proteins, nucleic acid molecules therefor, novel crystal structure of novel BACE proteins, and methods for making and using - Disclosed and claimed are novel BACE proteins, crystal structures thereof, nucleic acid molecules therefor, and methods for making and using and uses of the same, especially for ascertaining inhibitors of BACE; and thus, disclosed and claimed too are inhibitors of BACE and methods of making and using the same. | 12-04-2008 |
20080317726 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 12-25-2008 |
20090010910 | COMPOSITIONS AND METHODS FOR DERMATOLOGICAL WOUND HEALING - The invention relates to compositions for debriding damaged skin comprising at least one enzymatic debriding agent and at least one antiseptic compound comprising heavy metal ions. The present invention further relates to kit and methods for topical debridement of damaged skin, particularly of burned skin. | 01-08-2009 |
20090047266 | Lipases for Pharmaceutical Use - The pharmaceutical use of lipases related to a variant of the | 02-19-2009 |
20090053187 | Agent exhibiting bactericidal action with respect to vegetative and spore cells bacillus anthrasis, anthrax preventing and treating method - The invention relates to the field of biotechnology, medicine, and veterinary and can be used for anthrax prevention and treatment. The proposed drug has a bactericidal effect on vegetative and spore cells of | 02-26-2009 |
20090053188 | METHOD OF PREVENTING REDUCED FEED INTAKE IN ANIMALS AND TREATMENT OF DISEASE CONDITIONS - The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising one or more antibiotics. The present invention also relates to a method for treating laminitis and fermentative acidosis in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. The present invention further relates to a method for treating equine grass sickness and pulpy kidney in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. | 02-26-2009 |
20090060893 | Methods for enlarging the diameter of a biological conduit in a human subject - The invention provides methods for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 03-05-2009 |
20090092591 | Use of a Mixture of Superoxide Dismutase and Catalase for Treating Inflammatory Skin Lesions - The invention concerns the use of a mixture of superoxide dismutase and catalase for preparing a topical composition for treating inflammatory skin lesions, said lesions being selected among the group consisting of dermal fibroses, epidermal keratoses, cheloid scars or hypertrophic eschars. The inventive compositions are formulated to obtain all galenic forms conventionally used for applying a topical composition on the skin such as for example milk, cream, lotion, plaster or patch, as powder sticks to be solubilized in water or physiological serum prior to use. | 04-09-2009 |
20090110674 | Health supplement - A health supplement consisting of numerous ingredients from several general groups including: anti-aging, anti-oxidant, vitamins, minerals, and elemental substances including metals. The supplement is specifically formulated for maximizing synergistic interaction of the ingredients while eliminating harmful interaction among the ingredients. A holistic approach to health is followed with ingredients to aid all systems of the human body. By addressing all human body systems, the supplement acts as a precursor to anti-aging and, when body systems are detoxified and oxidation is controlled, the effect of aging may be reversed. | 04-30-2009 |
20090238811 | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials - Disclosed herein are a coating, a textile finish, a wax, elastomer, a filler, an adhesive, or a sealant, as well as polymeric materials such as a plastic, a laminate, a composite, that includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase) alone or in combination with other enzymes such as a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme, or an antimicrobial peptide. Also disclosed herein are methods of retarding or preventing microbial growth on or in a coating, paint, textile finish, wax, elastomer, adhesive, sealant, filler, or a polymeric material, where such a surface material includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase). | 09-24-2009 |
20090317371 | Method, Composition, and Device, for the Treatment of Amylase Malfunctions / Inactivity in Association with Saccharides (Mainly Polysaccharides) Based Diseases - Physiological protein and enzyme complex having active Trimethylglycine, active amylases, active lipases, and active proteases, of human (saliva enzymes), yeast, plant, fungi, and or microbial origin, preferably digestive enzyme complex such as, Trimethylglycine, 4-α-D-glucan glucanohydrolase; Exo-1,4-α-glucosidase; Beta-fructofuranosidase; Protease (3.0); Pectinase; Lipase; Cellulase; Lactase; Malt Diastase, or digestive enzyme complex containing proteins and enzymes for the treatment of high levels of saccharides and correction of amylases malfunctioning activity or inactivity in the body. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme complex having Trimethylglycine, amylolytic, lipolytic, and proteolytic activity, especially salivary, gastric, pancreatic and intestinal enzyme complex for the treatment of malfunctioning, or absent amylases enzymes activity but not deficiency, in association with or without excess saccharides in the body. | 12-24-2009 |
20090324571 | USE OF BACTERIAL AMYLASES IN FEED FOR BOVINE ANIMALS - The invention relates to the use of at least one bacterial amylase in feed for ruminant animals of the subfamily Bovinae in particular for improving milk yield, apparent digestibility of the diet fed, feedstuff dry matter disappearance, weight gain, and/or Feed Conversion Ratio (FCR). Examples of bovine animals are dairy cows and beef cattle. The invention also relates to the use of such amylases in feed and feed additives such as premix, concentrates and total mixed ration (TMR). The amylase may be used in combination with cellulase for improving milk yield and/or back fat thickness. Preferred amylases are derived from | 12-31-2009 |
20090324572 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF WILLIAMS SYNDROME - A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed. | 12-31-2009 |
20100034797 | Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the | 02-11-2010 |
20100040592 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF - Disclosed are compositions including crosslinked lipase crystals that are highly resistant to proteolysis, low pH and elevated temperature. | 02-18-2010 |
20100092447 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES - A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | 04-15-2010 |
20100111920 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VAGINAL DISEASES EMPLOYING PEROXIDE-PRODUCING ENZYMES AND PEROXIDASES - A therapeutic composition for vaginal administration based on the generation of a biocidal anion by an enzymatic reaction catalyzed by a peroxidase. The peroxide utilized by the peroxidase enzyme can be endogenous or can be generated by the action of an oxidase enzyme on a suitable substrate. Therapeutic compositions according to the present invention are useful for the treatment of vaginal diseases and conditions, including bacterial and fungal infections. | 05-06-2010 |
20100124548 | Pharmaceutical product - The present invention relates to methods and products for the treatment of any disorder or condition, which is associated with abnormal amount of non-collagenous protein, or abnormal oligomerization or dysfunction of non-collagenous protein, such as adiponectin in the blood circulation and/or tissue of a patient. The treatment comprises that functional form of the non-collagenous protein is adjusted in the blood circulation and/or tissue of the patient substantially to the level it is in the blood circulation and/or tissue of a healthy person, by using lysyl hydroxylase and/or glycosyl-transferase activities of LH3 or other lysyl hydroxylase to modify the non-collagenous protein to HMW or other functional form. | 05-20-2010 |
20100135978 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 06-03-2010 |
20100143320 | DIETARY SUPPLEMENT - The invention relates to a dietary supplement that promotes proper ingestion and proper digestion of animal and/or vegetable proteins. The supplement comprises an enzyme mixture containing amylase, lactase and bromelain in the following dosage by weight: 15 mg to 90 mg amylase, 18 mg to 90 mg lactase and 6 mg to 80 mg bromelain. | 06-10-2010 |
20100158885 | METHOD AND MATERIAL FOR SITE ACTIVATED COMPLEXING OF BIOLOGIC MOLECULES - Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities. | 06-24-2010 |
20100209411 | USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN EARS - A composition for removal of biofilm in the ears is useful for the treatment of ear infections such as otitis media, particularly those infections caused by | 08-19-2010 |
20100233146 | Coatings and Surface Treatments Having Active Enzymes and Peptides - Disclosed herein are a materials such as a coating, an elastomer, an adhesive, a sealant, a textile finish, a wax, and a filler for such a material, wherein the material includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme that degrades a cell wall and/or a cell membrane component (e.g., a lysozyme, a lytic transgrycosylase, a peptidase), and/or a biocidal or biostatic peptide. Also disclosed herein are methods of decontaminating a surface comprising such a material from a chemical substrate of an enzyme such as a lipid or an organophosphorus compound, as well as reducing the growth of a microorganism on or within such a material. | 09-16-2010 |
20100303785 | NOVEL THERAPEUTICS BASED ON TAU/MICROTUBULE DYNAMICS - The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics. | 12-02-2010 |
20100322912 | Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients - Combination enzyme products and methods of use thereof are provided. Aspergillopepsin I is combined with a protease enzyme that provides for an additive or synergistic effect in the digestion of toxic gluten oligopeptides. The enzyme products are useful in the treatment of Celiac Sprue patients, particularly for patients who continue to exhibit signs or symptoms of active disease despite following a gluten-free diet. | 12-23-2010 |
20110002906 | Purification and Isolation of Recombinant Oxalate Degrading Enzymes and Spray-Dried Particles Containing Oxalate Degrading Enzymes - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions. | 01-06-2011 |
20110044966 | USE OF A SUBSTANCE FOR MANUFACTURING OF A MEDICAMENT FOR TREATMENT OF COMMON COLD - A method for treatment and/or prevention of common cold caused by rhinovirus, wherein a patient in need is treated with a medicament including a hydrogen peroxide producing enzyme. | 02-24-2011 |
20110059062 | USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN AIRWAY PASSAGES - A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by | 03-10-2011 |
20110064712 | Dietary Supplement Compositions and Methods of Making and Using the Same - Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed. | 03-17-2011 |
20110091436 | USE OF MATRIX METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC TREATMENTS - The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders. | 04-21-2011 |
20110110910 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 05-12-2011 |
20110123508 | INSTRUMENT CLEANER - A composition or concentrate for cleaning medical or dental instruments comprising in combination a protease and a biostatically effective phenoxy alcohol such as phenoxyethanol selected such that at a working solution dilution of the combination, the phenoxy alcohol is at a concentration below the MIC of the selected phenoxy alcohol against | 05-26-2011 |
20110129454 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 06-02-2011 |
20110135621 | INHIBITING BACTERIAL INFECTION AND BIOFILM FORMATION - The present invention relates generally to the field of treating bacterial infections. More particularly, it relates to an antimicrobial agent and methods of eliminating biofilm and planktonic cells using the antimicrobial agent. | 06-09-2011 |
20110150855 | Enzyme Composition and Use Thereof - Disclosed is a means effective for the treatment or prevention of inflammatory bowel disease. Specifically disclosed is an enzyme composition for the treatment or prevention of inflammatory bowel disease, which utilizes an enzyme capable of producing an oligosaccharide in vivo. | 06-23-2011 |
20110158972 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 06-30-2011 |
20110171189 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 07-14-2011 |
20110177048 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms. | 07-21-2011 |
20110177049 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 07-21-2011 |
20110177050 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 07-21-2011 |
20110182873 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 07-28-2011 |
20110182874 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms. | 07-28-2011 |
20110189153 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 08-04-2011 |
20110195059 | Enzymatic Prevention and Control of Biofilm - The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm. | 08-11-2011 |
20110200574 | USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides. | 08-18-2011 |
20110200575 | METALLO-LACTOFERRIN-COENZYME COMPOSITIONS TO IMPROVE SLEEP PATTERNS - Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms. | 08-18-2011 |
20110243908 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 10-06-2011 |
20110243909 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 10-06-2011 |
20110280853 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES - Compositions and methods for treating or preventing | 11-17-2011 |
20110280854 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES - Compositions and methods for treating or preventing | 11-17-2011 |
20120070423 | ORAL COMPOSITION AND METHOD OF FORMING AND USING SAME - An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria. | 03-22-2012 |
20120107296 | FEED SUPPLEMENT - The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5. | 05-03-2012 |
20120148554 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress. | 06-14-2012 |
20120171187 | DEBRIDING COMPOSITION FROM BROMELAIN AND METHODS OF PRODUCTION THEREOF - The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing. | 07-05-2012 |
20120177624 | ORAL DISINFECTANT, AND FOOD ADDITIVE COMPRISING THE DISINFECTANT - Disclosed is a disinfectant which is safe, has few adverse side-effects, can be ingested together with a food or beverage by adding the disinfectant to the food or beverage, shows a bactericidal effect in the oral cavity, and has no problem even when ingested on a daily basis over a long period. Also disclosed is a food additive comprising the disinfectant. Specifically, disclosed is an oral disinfectant for the disinfection of an oral bacterium, which comprises lactoperoxidase, glucose oxidase, glucose and a pH-adjusting component. | 07-12-2012 |
20120207732 | COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL OUTGROWTH - Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration. | 08-16-2012 |
20120230970 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. | 09-13-2012 |
20120251516 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT - The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells. | 10-04-2012 |
20120263699 | Compositions and Methods for Preservation of Fresh Produce - The present invention is concerned with compositions and methods for treatment of fresh produce to reduce the levels of bacterial and/or fungal contamination. The compositions comprise the ingredients selected from a source of chlorite ions, enzymes, grapefruit seed extract, and an agent for adjusting the pH of the composition, and a pH buffering system to maintain a stable pH. The methods of preserving produce include applying the compositions to produce, to the trees or plants that bear produce, or to the packing materials used to pack, ship and sell the produce. | 10-18-2012 |
20120276074 | COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION - The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage. | 11-01-2012 |
20120276075 | SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES - The present invention relates to a novel enzyme composition comprising a prolyl protease and tripeptidyl proteases having unique catalytic properties. The present invention further relates to methods for producing the enzyme composition as well as a pharmaceutical composition and a food supplement containing the enzyme composition and its use in the degradation of polypeptides. | 11-01-2012 |
20120308543 | Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the | 12-06-2012 |
20120315260 | Compositions and Methods to Prevent and Treat Biofilms - Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings. | 12-13-2012 |
20120315261 | ANTIBACTERIAL AUXILIARY AGENT COMPRISING KOMBU EXTRACT AS ACTIVE INGREDIENT, ANTIBACTERIAL COMPOSITION, AND FOOD OR BEVERAGE - Disclosed are: a method for utilizing a kombu (kelp) extract as an antibacterial auxiliary agent; and a method for utilizing a combination of the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose as an antibacterial composition having a potent antibacterial activity. Specifically disclosed are: an antibacterial auxiliary agent comprising a fraction having a molecular weight of 5000 or less and produced from a kombu extract as an active ingredient; an antibacterial composition comprising the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose; an antibacterial composition as mentioned above, which additionally comprises xanthane gum; and a food or beverage containing the antibacterial composition. | 12-13-2012 |
20120321605 | ARTIFICIAL SALIVA COMPRISING HYALULONIC ACID - Provided is artificial saliva including hyaluronic acid (HA). The artificial saliva may be used to treat xerostomia or oral candidiasis and can be effectively used to prevent or treat complications cased by reduced secretion of saliva, since the artificial saliva is in a physiological range of human saliva and shows adequate antimicrobial activities. | 12-20-2012 |
20120328589 | GLUCOCEREBROSIDASE MULTIMERS AND USES THEREOF - Multimeric protein structures comprising at least two glucocerebrosidase molecules being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and uses thereof in the treatment of Gaucher disease. The multimeric protein structures are characterized by longer-lasting activity as compared to native glucocerebrosidase both in serum and in lysosomes. | 12-27-2012 |
20130034529 | NATURAL COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING - Compositions comprising honey, myrhh, and | 02-07-2013 |
20130034530 | Dietary Supplement Cognitive Support System - The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function. | 02-07-2013 |
20130034531 | USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides. | 02-07-2013 |
20130034532 | NANOZYMES, METHODS OF MAKING NANOZYMES, AND METHODS OF USING NANOZYMES - Embodiments of the present disclosure provides for nanozymes, methods of making nanozymes, methods of using nanozymes, and the like. | 02-07-2013 |
20130058910 | DECONTAMINATION OF CHEMICAL AND BIOLOGICAL AGENTS - A system includes at least one oxidase. at least one haloperoxidase; at least a first polymer including groups exhibiting nucleophilic activity for organophosphorus compounds, and a source of halide ions to serve as a substrate for haloperoxidase-catalyzed generation of halogens. The source of halide ions may, for example, include salt crystals or a salt in an extended release system. In a number of embodiments, the first polymer includes halide ions. | 03-07-2013 |
20130095090 | FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT - Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate. | 04-18-2013 |
20130115203 | Enzyme and Prebiotic Combinations for Enhancing Probiotic Efficacy - This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and α-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and β-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts. | 05-09-2013 |
20130121982 | ANTIDOTE TO THE BITE OF VENOMOUS SNAKES - The present invention concerns a composition comprising a low dosage of at least one venom derived from a venomous snake, characterised in that said composition is diluted in an aqueous medium according to the Sequential Kinetic Activation method. In addition, the present invention concerns the use of said composition as an antidote against the poisoning caused by the bite of a venomous snake. | 05-16-2013 |
20130129697 | Enhanced Staphylolytic Activity of the Staphylococcus aureus Bacteriophage vB_SauS-philPLA88 Virion-Associated Peptidoglycan Hydrolase HydH5: Fusions, Deletions and Synergy with LysH5 - Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Full-length HydH5, a virion-associated peptidoglycan hydrolase from the | 05-23-2013 |
20130129698 | CONJUGATED BLOOD COAGULATION FACTOR VIIA - The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa. | 05-23-2013 |
20130129699 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a | 05-23-2013 |
20130142770 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example. | 06-06-2013 |
20130149292 | THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials. | 06-13-2013 |
20130171121 | MATURATION OF GASTROINTESTINAL TRACT - The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation. | 07-04-2013 |
20130189238 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 07-25-2013 |
20130195828 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 08-01-2013 |
20130224171 | AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE - 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed. | 08-29-2013 |
20130224172 | METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS - Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. | 08-29-2013 |
20130236439 | ENZYME-ACTIVATED COLLAGEN AND TISSUE MATRICES - Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue. | 09-12-2013 |
20130259848 | ENZYME COMBINATIONS TO REDUCE BRAIN TISSUE SWELLING - Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure. | 10-03-2013 |
20130266552 | LIQUID SURFACTANT PREPARATION CONTAINING LIPASE AND PHOSPHONATE - A liquid surfactant preparation comprises a phosphonate and has an advantageous lipolytic activity. This is achieved by using a lipase that is naturally present in a microorganism, the microorganism being | 10-10-2013 |
20130273020 | ANTIFUNGAL COMPOSITION - Compositions are described with an unexpectedly greater yeast growth inhibitory effect than the individual components alone. The compositions include a mixture of honey, a honey analogue or a honey fraction along with lactoferrin protein. The combination has a synergistic effect in inhibiting yeast growth. | 10-17-2013 |
20130280228 | FEED SUPPLEMENT - The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5. | 10-24-2013 |
20130323219 | COMPOSITION COMPRISING A COMBINATION OF AT LEAST ONE PROTEOLYTIC ENZYME AND AT LEAST ONE LIPOLYTIC ENZYME, FOR USE IN PREVENTING TRIGLYCERIDE SYNTHESIS - The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight. | 12-05-2013 |
20130336946 | FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS - The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection. | 12-19-2013 |
20140004094 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES | 01-02-2014 |
20140017220 | TREATMENT OF OPHTHALMIC CONDITIONS - Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system. | 01-16-2014 |
20140044694 | PHARMACEUTICAL COMPOSITION FOR TREATING LYSOSOMAL STORAGE DISEASE - The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease. | 02-13-2014 |
20140105880 | USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES - The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain harrier. | 04-17-2014 |
20140127180 | MUTANT CYTOCHROME P450 2B6 PROTEINS AND USES THEREOF - The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy. | 05-08-2014 |
20140134146 | POLYSILOXANE-BASED FOULING RELEASE COATS INCLUDING ENZYMES - The present application discloses a fouling release cured paint coat comprising a polysiloxane-based binder matrix constituting at least 40% by dry weight of the coat, and one or more enzymes. The application further discloses a kit for preparing a fouling release coat, a coating composition comprising a polysiloxane-based binder system comprising one or more polysiloxane components modified with hydrophilic oligomer/polymer moieties, and one or more enzymes, and a coating composition comprising a polysiloxane-based binder system, 0.01-20% by dry weight of one or more hydrophilic-modified polysiloxane oils, and one or more enzymes. | 05-15-2014 |
20140140975 | TREATMENTS INVOLVING GLUTAREDOXINS AND SIMILAR AGENTS - The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like. | 05-22-2014 |
20140154229 | PROTEOLYTIC EXTRACT FROM BROMELAIN FOR THE TREATMENT OF CONNECTIVE TISSUE DISORDERS - The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease. | 06-05-2014 |
20140248250 | AGENT EXHIBITING BACTERICIDAL ACTION WITH RESPECT TO VEGETATIVE AND SPORE CELLS BACILLUS ANTHRACIS, ANTHRAX PREVENTING AND TREATING METHOD - The drug has a bactericidal effect on vegetative and spore cells of | 09-04-2014 |
20140248251 | Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance - The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pharmaceutical compositions for protecting a subject in need from a deleterious effect of gluten ingestion, and, in particular, for treating celiac disease and gluten intolerance. Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten. | 09-04-2014 |
20140271597 | TREATMENT OF OPHTHALMIC CONDITIONS - Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system. | 09-18-2014 |
20140286924 | AGENT FOR USE IN THE CASE OF DISORDERS OF BLOOD SUGAR METABOLISM, INCLUDING DIABETES - An agent for use in the case of disorders of blood sugar metabolism, including diabetes, is described, which reduces the glucose content of food and other substances with the help of 5-D-fructose dehydrogenase and glucose isomerase. | 09-25-2014 |
20140302000 | PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN - Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans. | 10-09-2014 |
20140314732 | CROSS-LINKED COMPOSITIONS - Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG). | 10-23-2014 |
20140322190 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 10-30-2014 |
20140328818 | Proteases for Degrading Gluten - Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance. | 11-06-2014 |
20150064156 | CHIMERIC BACTERIOPHAGE LYSIN WITH ACTIVITY AGAINST STAPHYLOCOCCI BACTERIA - The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant | 03-05-2015 |
20150079061 | METHOD FOR THE HARVESTING, PROCESSING, AND STORAGE OF PROTEINS FROM THE MAMMALIAN FETO-PLACENTAL UNIT AND USE OF SUCH PROTEINS IN COMPOSITIONS AND MEDICAL TREATMENT - The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid. The invention further provides method of treatment of a disease or aging in a mammalian subject including administering to the mammalian subject a plurality of proteins from at least one blast frozen component harvested from a mammalian feto-placental unit; and reducing an accumulation of at least one intracellular protein in the subject. | 03-19-2015 |
20150079062 | METHOD FOR HARVESTING, PROCESSING, AND STORAGE OF PROTEINS FROM THE MAMMALIAN FETO-PLACENTAL UNIT AND USE OF SUCH PROTEINS IN COMPOSITIONS AND MEDICAL TREATMENT - The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid. The invention further provides method of treatment of a disease or aging in a mammalian subject including administering to the mammalian subject a plurality of proteins from at least one blast frozen component harvested from a mammalian feto-placental unit; and reducing an accumulation of at least one intracellular protein in the subject. | 03-19-2015 |
20150093369 | MIXTURE OF ENZYMES FROM ANTARCTIC KRILL FOR USE IN THE REMOVAL OF A BIOFILM - The invention concerns a mixture of enzymes from krill for use in the treatment of a soft tissue including epithelial tissue and mucosa on which soft tissue a biofilm has formed or is expected to form, which soft tissue is a soft tissue of a mammal and which treatment comprises the removal of the biofilm or preventing a formation of the biofilm. | 04-02-2015 |
20150098932 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 04-09-2015 |
20150110765 | Polypeptides Having Alpha-Glucuronidase Activity And Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains. | 04-23-2015 |
20150118211 | Enzymatic Prevention and Control of Biofilm - The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm. | 04-30-2015 |
20150132273 | Nutritional Compositions and Methods for Treating Cognitive Impairment - A nutritional supplement that contains folinic acid, folic acid, USP, methylfolic acid, cobalamin, magnesium, docosahexaenoic acid, phosphatidylcholine-docosahexaenoic acid, phosphatidylethanolamine-docosahexaenoic acid. | 05-14-2015 |
20150297544 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION - A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome. | 10-22-2015 |
20150297684 | Extended Length Botulinum Toxin Formulation for Human or Mammalian Use - An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule is disclosed. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed. | 10-22-2015 |
20150297690 | NOVEL PROTEIN MATERIAL - The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20. | 10-22-2015 |
20150306132 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 10-29-2015 |
20150328362 | THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials. | 11-19-2015 |
20150343029 | NOVEL CHEESE AND METHOD FOR PRODUCING THE SAME - The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33. | 12-03-2015 |
20150343030 | BEVERAGE, AND METHOD OF PRODUCING THE SAME - The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23. | 12-03-2015 |
20150343034 | COMPOSITIONS AND METHODS FOR COUNTERACTING FACTOR XA INHIBITION - The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa. | 12-03-2015 |
20150352195 | Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance - Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten. | 12-10-2015 |
20150359860 | METHOD OF TREATING FIBROSIS IN SKELETAL MUSCLE TISSUE - A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents. | 12-17-2015 |
20150374797 | MILK-DERIVED BASIC PROTEIN FRACTION AS SKIN SENSITIVITY IMPROVING AGENT - A skin sensitivity improving agent which is safe and, when routinely taken or applied to the skin, exerts an effect of improving deterioration in peripheral sensation is provided. The present invention also provides a food, a drink, a feed or a cosmetic for improving sensation which exerts an effect of improving deterioration in peripheral sensation when orally taken or applied to the skin. The skin sensitivity improving agent includes, as the active ingredient, a basic protein fraction derived from milk or a degraded basic protein fraction derived from milk. By orally taking the basic protein fraction derived from milk or the degraded basic protein fraction derived from milk or applying the same directly to the skin, deterioration in sensation, in particular, peripheral sensation can be improved. Thus, a food, a drink, a feed or a cosmetic for improving sensation can be obtained. | 12-31-2015 |
20160030527 | Compositions and Methods for Treatment of Stroke - The present invention provides compositions and methods for treating stroke. The invention relates to inhibiting the level and/or activity of cell debris after the onset of stroke. In certain embodiments, the invention provides for the catabolism or inhibition of at least one of extracellular RNA, extracellular DNA, and extracellular ATP. | 02-04-2016 |
20160053250 | MATRIX METALLOPROTEINASSES AND USES THEREOF - Matrix metalloproteinases (MMPs) compositions, inactive forms of MMPs (e.g. proMMPs), fragments, mutants, variants or combinations thereof. A pharmaceutical composition comprises one or more of the above in a pharmaceutical carrier. A composition comprises at least one of: a matrix metalloproteinase (MMP), an inactive MMP or a proenzyme (proMMP) thereof, wherein the matrix metalloproteinase (MMPs), inactive MMPs or proMMPs thereof, comprise: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13.MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-23B, MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, active fragments, mutants, variants or any combinations thereof. The uses include isolation of cells, in particular stem cells, from tissues, dissociation of tissues, proteins and treatment of a variety of conditions. | 02-25-2016 |
20160090585 | ISOMERASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having isomerase activity, e.g., racemase activity, e.g., amino acid racemase activity, alanine racemase activity, and/or epimerase activity, and/or catalyze the re-arrangement of atoms within a molecule, catalyze the conversion of one isomer into another, catalyze the conversion of an optically active substrate into a raceme, which is optically inactive, catalyze the interconversion of substrate enantiomers, catalyze the stereochemical inversion around the asymmetric carbon atom in a substrate having only one center of asymmetry, catalyze the stereochemical inversion of the configuration around an asymmetric carbon atom in a substrate having more than one asymmetric center, and/or catalyze the racemization of amino acids. Thus, the invention provides enzymes, compositions, methods for production of pharmaceutical compositions, pharmaceutical intermediates, antibiotics, sweeteners, peptide enzymes, peptide hormones, fuel and fuel additive compositions, foods and food additives, beverage and beverage additives, feeds and feed additives, drugs and drug additives, dietary supplements, textiles, wood, paper, pulp, and detergents comprising the polypeptides or polynucleotides in accordance with the invention. | 03-31-2016 |
20160101165 | COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME - A debridement enzyme for necrotic tissue is described that is not dependent upon proteolytic enzymatic activity but instead utilizes the amylase family of enzymes. The amylases (α-, β-, γ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that α-amylase is effective in the debridement of devitalized tissue. | 04-14-2016 |
20160101166 | COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME - A treatment for pruritus is described that is based upon amylase. The amylases (α-, β-, γ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that α-amylase is effective in the reduction of pruritus (itching) of affected tissue. | 04-14-2016 |
20160114005 | HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN - A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G | 04-28-2016 |
20160114012 | ENZYME FORMULATION FOR USE AS FOOD SUPPLEMENT - The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder. | 04-28-2016 |
20160122743 | METHODS FOR REMOVING VIRAL CONTAMINANTS FROM PANCREATIC EXTRACTS - Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided. | 05-05-2016 |
20160143843 | SKIN CREAM - The present disclosure encompasses formulations, and methods of manufacture and use thereof, for topical application to and conditioning of human skin. The formulations disclosed comprise an effective amount of at least one steroidal agent, plant extract, viscosity-adjusting agent, anti-oxidant. In particular, the formulations comprise an effective amount micronized progesterone and are used for topical application to the skin of men. | 05-26-2016 |
20160144004 | Use of Hydrolytic and Oxidative Enzymes to Dissolve Biofilm in Airway Passages - A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by | 05-26-2016 |
20170232077 | COMPOSITIONS AND METHODS FOR TREATING GLUTEN INTOLERANCE AND DISORDERS ARISING THEREFROM | 08-17-2017 |
20170232079 | METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV | 08-17-2017 |
20180021445 | USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES | 01-25-2018 |
20190142910 | METHODS OF DEBRIDEMENT OF CHRONIC WOUNDS | 05-16-2019 |
20190145954 | VISCOELASTIC ANALYSIS IN PATIENTS WITH DISEASE ASSOCIATED WITH CARDIOVASCULAR SYSTEM | 05-16-2019 |